DNA Script signed distribution agreements to place its benchtop SYNTAX platform with partners in Latin America (Gencell), South Korea (Bio‑Medical Science Co.) and Japan (BioStream). The deals aim to decentralize oligonucleotide supply chains and reduce lead times for local researchers by enabling in‑lab, on‑demand single‑stranded DNA synthesis. CEO Marc Montserrat framed the expansion as part of a strategy to make oligo production geography‑agnostic and to support regional biomanufacturing capacity—an operational shift that could affect timelines for academic and small‑biotech programs reliant on rapid oligo access.